JP2016512193A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512193A5 JP2016512193A5 JP2015561536A JP2015561536A JP2016512193A5 JP 2016512193 A5 JP2016512193 A5 JP 2016512193A5 JP 2015561536 A JP2015561536 A JP 2015561536A JP 2015561536 A JP2015561536 A JP 2015561536A JP 2016512193 A5 JP2016512193 A5 JP 2016512193A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- bromophenyl
- optionally substituted
- carbamoyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 46
- 229910052739 hydrogen Inorganic materials 0.000 claims 34
- 239000001257 hydrogen Substances 0.000 claims 33
- 150000002431 hydrogen Chemical class 0.000 claims 29
- 125000003118 aryl group Chemical group 0.000 claims 25
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 9
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 206010023332 keratitis Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000003367 polycyclic group Chemical group 0.000 claims 3
- DMYSYIXHXMXWBW-UHFFFAOYSA-N 1-(4-bromophenyl)-3-(4-ethyl-2,5-dioxo-4-propan-2-ylimidazolidin-1-yl)urea Chemical compound O=C1C(CC)(C(C)C)NC(=O)N1NC(=O)NC1=CC=C(Br)C=C1 DMYSYIXHXMXWBW-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- ZCVLAKQKEWQJAO-CQSZACIVSA-N (2r)-2-[(4-bromophenyl)carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](C(=O)O)NC(=O)NC=1C=CC(Br)=CC=1)C1=CC=CC=C1 ZCVLAKQKEWQJAO-CQSZACIVSA-N 0.000 claims 1
- ARFPPUXKLADSLY-CQSZACIVSA-N (2r)-2-[(4-iodophenyl)carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](C(=O)O)NC(=O)NC=1C=CC(I)=CC=1)C1=CC=CC=C1 ARFPPUXKLADSLY-CQSZACIVSA-N 0.000 claims 1
- DAIPOHPEAYKUFJ-JTQLQIEISA-N (2s)-2-[(4-bromo-2-fluorophenyl)carbamoylamino]-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)NC1=CC=C(Br)C=C1F DAIPOHPEAYKUFJ-JTQLQIEISA-N 0.000 claims 1
- IUIJFVKTIGTRLF-AWEZNQCLSA-N (2s)-2-[(4-bromo-2-fluorophenyl)carbamoylamino]-4-methyl-n-(2-oxopropyl)pentanamide Chemical compound CC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1F IUIJFVKTIGTRLF-AWEZNQCLSA-N 0.000 claims 1
- ISXHVEOMRHCILC-INIZCTEOSA-N (2s)-2-[(4-bromo-2-fluorophenyl)carbamoylamino]-n-(2-hydroxyethyl)-3-phenylpropanamide Chemical compound C([C@@H](C(=O)NCCO)NC(=O)NC=1C(=CC(Br)=CC=1)F)C1=CC=CC=C1 ISXHVEOMRHCILC-INIZCTEOSA-N 0.000 claims 1
- BIPYNHXPZUAITO-KRWDZBQOSA-N (2s)-2-[(4-bromo-2-fluorophenyl)carbamoylamino]-n-(2-oxopropyl)-3-phenylpropanamide Chemical compound C([C@@H](C(=O)NCC(=O)C)NC(=O)NC=1C(=CC(Br)=CC=1)F)C1=CC=CC=C1 BIPYNHXPZUAITO-KRWDZBQOSA-N 0.000 claims 1
- MUTURHQUUWAQAJ-ZDUSSCGKSA-N (2s)-2-[(4-bromophenyl)carbamoylamino]-2-phenylacetic acid Chemical compound N([C@H](C(=O)O)C=1C=CC=CC=1)C(=O)NC1=CC=C(Br)C=C1 MUTURHQUUWAQAJ-ZDUSSCGKSA-N 0.000 claims 1
- VMEDZAKIZFAOJL-JTQLQIEISA-N (2s)-2-[(4-bromophenyl)carbamoylamino]-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)NC1=CC=C(Br)C=C1 VMEDZAKIZFAOJL-JTQLQIEISA-N 0.000 claims 1
- ZCVLAKQKEWQJAO-AWEZNQCLSA-N (2s)-2-[(4-bromophenyl)carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)NC=1C=CC(Br)=CC=1)C1=CC=CC=C1 ZCVLAKQKEWQJAO-AWEZNQCLSA-N 0.000 claims 1
- JLYOCBBJLCFPLC-AWEZNQCLSA-N (2s)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-n-(2-oxopropyl)pentanamide Chemical compound CC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 JLYOCBBJLCFPLC-AWEZNQCLSA-N 0.000 claims 1
- WNZAMPDJJNIFRR-LBPRGKRZSA-N (2s)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-n-(2h-tetrazol-5-ylmethyl)pentanamide Chemical compound N([C@@H](CC(C)C)C(=O)NCC=1NN=NN=1)C(=O)NC1=CC=C(Br)C=C1 WNZAMPDJJNIFRR-LBPRGKRZSA-N 0.000 claims 1
- WCGZSGWHOKVWEC-AWEZNQCLSA-N (2s)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-n-[(3-oxo-1,2-oxazol-5-yl)methyl]pentanamide Chemical compound N([C@@H](CC(C)C)C(=O)NCC=1ON=C(O)C=1)C(=O)NC1=CC=C(Br)C=C1 WCGZSGWHOKVWEC-AWEZNQCLSA-N 0.000 claims 1
- HJRBAXCENNDVGX-AWEZNQCLSA-N (2s)-2-[(4-bromophenyl)carbamoylamino]-n-(1,3-dihydroxypropan-2-yl)-4-methylpentanamide Chemical compound OCC(CO)NC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 HJRBAXCENNDVGX-AWEZNQCLSA-N 0.000 claims 1
- MEHDWYDBOQKHNL-KZUDCZAMSA-N (2s)-2-[(4-bromophenyl)carbamoylamino]-n-(2,3-dihydroxypropyl)-4-methylpentanamide Chemical compound OCC(O)CNC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 MEHDWYDBOQKHNL-KZUDCZAMSA-N 0.000 claims 1
- DMTOJWVPPCFMFC-INIZCTEOSA-N (2s)-2-[(4-bromophenyl)carbamoylamino]-n-(2-hydroxyethyl)-3-phenylpropanamide Chemical compound C([C@@H](C(=O)NCCO)NC(=O)NC=1C=CC(Br)=CC=1)C1=CC=CC=C1 DMTOJWVPPCFMFC-INIZCTEOSA-N 0.000 claims 1
- HIASXAKDYOCRPQ-ZDUSSCGKSA-N (2s)-2-[(4-bromophenyl)carbamoylamino]-n-(2-hydroxyethyl)-4-methylpentanamide Chemical compound OCCNC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 HIASXAKDYOCRPQ-ZDUSSCGKSA-N 0.000 claims 1
- DSBITWRMTGDNTD-RISCZKNCSA-N (2s)-2-[(4-bromophenyl)carbamoylamino]-n-[(2r)-1-hydroxypropan-2-yl]-4-methylpentanamide Chemical compound OC[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 DSBITWRMTGDNTD-RISCZKNCSA-N 0.000 claims 1
- SPSDTWCAZAFLNC-AWEZNQCLSA-N (2s)-2-[(4-bromophenyl)carbamoylamino]-n-[2-(dimethylamino)-2-oxoethyl]-4-methylpentanamide Chemical compound CN(C)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 SPSDTWCAZAFLNC-AWEZNQCLSA-N 0.000 claims 1
- BEVMVJHUDJGQIZ-ZANVPECISA-N (2s)-2-[[(2s)-2-[(4-bromo-2-fluorophenyl)carbamoylamino]-4-methylpentanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1F BEVMVJHUDJGQIZ-ZANVPECISA-N 0.000 claims 1
- HILAEZFSMOFJEY-ROUUACIJSA-N (2s)-2-[[(2s)-2-[(4-bromophenyl)carbamoylamino]-4-methylpentanoyl]amino]-2-phenylacetic acid Chemical compound N([C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)C=1C=CC=CC=1)C(=O)NC1=CC=C(Br)C=C1 HILAEZFSMOFJEY-ROUUACIJSA-N 0.000 claims 1
- AMMVIGUFZGQAQO-GJZGRUSLSA-N (2s)-2-[[(2s)-2-[(4-bromophenyl)carbamoylamino]-4-methylpentanoyl]amino]-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 AMMVIGUFZGQAQO-GJZGRUSLSA-N 0.000 claims 1
- LZDASXAVFDPLHY-GJZGRUSLSA-N (2s)-2-[[(2s)-2-[(4-bromophenyl)carbamoylamino]-4-methylpentanoyl]amino]pentanoic acid Chemical compound CCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 LZDASXAVFDPLHY-GJZGRUSLSA-N 0.000 claims 1
- VEUKJHBVYFMVSW-GWCFXTLKSA-N (2s)-2-[[(2s)-2-[(4-bromophenyl)carbamoylamino]-4-methylpentanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 VEUKJHBVYFMVSW-GWCFXTLKSA-N 0.000 claims 1
- JFQFHPOCFBTXQU-LBPRGKRZSA-N (2s)-4-methyl-n-(2h-tetrazol-5-ylmethyl)-2-[[4-(trifluoromethyl)phenyl]carbamoylamino]pentanamide Chemical compound N([C@@H](CC(C)C)C(=O)NCC=1NN=NN=1)C(=O)NC1=CC=C(C(F)(F)F)C=C1 JFQFHPOCFBTXQU-LBPRGKRZSA-N 0.000 claims 1
- SNQFANBVVDVQEX-LBPRGKRZSA-N (2s)-n-(2-amino-2-oxoethyl)-2-[(4-bromo-2-fluorophenyl)carbamoylamino]-4-methylpentanamide Chemical compound NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1F SNQFANBVVDVQEX-LBPRGKRZSA-N 0.000 claims 1
- JYWZBPJPSWXWPV-NSHDSACASA-N (2s)-n-(2-amino-2-oxoethyl)-2-[(4-bromo-2-fluorophenyl)carbamoylamino]pentanamide Chemical compound NC(=O)CNC(=O)[C@H](CCC)NC(=O)NC1=CC=C(Br)C=C1F JYWZBPJPSWXWPV-NSHDSACASA-N 0.000 claims 1
- OYFVBKKHXOLILR-LBPRGKRZSA-N (2s)-n-(2-amino-2-oxoethyl)-2-[(4-bromophenyl)carbamoylamino]-4-methylpentanamide Chemical compound NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 OYFVBKKHXOLILR-LBPRGKRZSA-N 0.000 claims 1
- OAEMFLAPEVPJGH-NSHDSACASA-N (2s)-n-(2-amino-2-oxoethyl)-2-[(4-bromophenyl)carbamoylamino]pentanamide Chemical compound NC(=O)CNC(=O)[C@H](CCC)NC(=O)NC1=CC=C(Br)C=C1 OAEMFLAPEVPJGH-NSHDSACASA-N 0.000 claims 1
- YLBUEARKTSANET-GJZGRUSLSA-N (2s)-n-[(2s)-1-amino-3-methyl-1-oxobutan-2-yl]-2-[(4-bromophenyl)carbamoylamino]-4-methylpentanamide Chemical compound CC(C)[C@@H](C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 YLBUEARKTSANET-GJZGRUSLSA-N 0.000 claims 1
- WVLHIJZNLYUXDZ-CPCISQLKSA-N (2s,3s)-2-[(4-bromo-2-fluorophenyl)carbamoylamino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)NC1=CC=C(Br)C=C1F WVLHIJZNLYUXDZ-CPCISQLKSA-N 0.000 claims 1
- QAFHGJAQMYSDFZ-HZMBPMFUSA-N (2s,3s)-2-[(4-bromophenyl)carbamoylamino]-3-methyl-n-(2-oxopropyl)pentanamide Chemical compound CC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)NC1=CC=C(Br)C=C1 QAFHGJAQMYSDFZ-HZMBPMFUSA-N 0.000 claims 1
- VEYCFNXDYFEYRJ-KWQFWETISA-N (2s,3s)-2-[(4-bromophenyl)carbamoylamino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)NC1=CC=C(Br)C=C1 VEYCFNXDYFEYRJ-KWQFWETISA-N 0.000 claims 1
- OQPOYHLMRHLEPF-SDBXPKJASA-N (2s,3s)-n-(2-amino-2-oxoethyl)-2-[(4-bromo-2-fluorophenyl)carbamoylamino]-3-methylpentanamide Chemical compound NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)NC1=CC=C(Br)C=C1F OQPOYHLMRHLEPF-SDBXPKJASA-N 0.000 claims 1
- RPGZGKDZPQRGRV-ZANVPECISA-N (2s,3s)-n-(2-amino-2-oxoethyl)-2-[(4-bromophenyl)carbamoylamino]-3-methylpentanamide Chemical compound NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)NC1=CC=C(Br)C=C1 RPGZGKDZPQRGRV-ZANVPECISA-N 0.000 claims 1
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 claims 1
- XEVINRXCIAOXHU-UHFFFAOYSA-N 1-(2-fluorophenyl)-3-[4-methyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]urea Chemical compound N1C(=O)N(NC(=O)NC=2C(=CC=CC=2)F)C(=O)C1(C)CCC1=CC=CC=C1 XEVINRXCIAOXHU-UHFFFAOYSA-N 0.000 claims 1
- IMUUQAIZKAMZSY-UHFFFAOYSA-N 1-(4-bromo-2-fluorophenyl)-3-(4,4-diethyl-2,5-dioxoimidazolidin-1-yl)urea Chemical compound O=C1C(CC)(CC)NC(=O)N1NC(=O)NC1=CC=C(Br)C=C1F IMUUQAIZKAMZSY-UHFFFAOYSA-N 0.000 claims 1
- WIMHNGNXVXEQGZ-UHFFFAOYSA-N 1-(4-bromo-2-fluorophenyl)-3-(4-ethyl-2,5-dioxo-4-propan-2-ylimidazolidin-1-yl)urea Chemical compound O=C1C(CC)(C(C)C)NC(=O)N1NC(=O)NC1=CC=C(Br)C=C1F WIMHNGNXVXEQGZ-UHFFFAOYSA-N 0.000 claims 1
- MMKCRMGUBFIZFI-UHFFFAOYSA-N 1-(4-bromo-2-fluorophenyl)-3-[4-[2-(2-hydroxyphenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl]urea Chemical compound N1C(=O)N(NC(=O)NC=2C(=CC(Br)=CC=2)F)C(=O)C1(C)CCC1=CC=CC=C1O MMKCRMGUBFIZFI-UHFFFAOYSA-N 0.000 claims 1
- RTSHUPJIMHKRNG-UHFFFAOYSA-N 1-(4-bromo-2-fluorophenyl)-3-[4-[2-(3-fluoro-4-hydroxyphenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl]urea Chemical compound N1C(=O)N(NC(=O)NC=2C(=CC(Br)=CC=2)F)C(=O)C1(C)CCC1=CC=C(O)C(F)=C1 RTSHUPJIMHKRNG-UHFFFAOYSA-N 0.000 claims 1
- ZQLXEUGZZBJOPW-UHFFFAOYSA-N 1-(4-bromo-2-fluorophenyl)-3-[4-[2-(3-hydroxyphenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl]urea Chemical compound N1C(=O)N(NC(=O)NC=2C(=CC(Br)=CC=2)F)C(=O)C1(C)CCC1=CC=CC(O)=C1 ZQLXEUGZZBJOPW-UHFFFAOYSA-N 0.000 claims 1
- CNTTUVKUTSBXPI-UHFFFAOYSA-N 1-(4-bromo-2-fluorophenyl)-3-[4-[2-(4-hydroxyphenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl]urea Chemical compound N1C(=O)N(NC(=O)NC=2C(=CC(Br)=CC=2)F)C(=O)C1(C)CCC1=CC=C(O)C=C1 CNTTUVKUTSBXPI-UHFFFAOYSA-N 0.000 claims 1
- VRTVMFISQDKPQM-UHFFFAOYSA-N 1-(4-bromo-2-fluorophenyl)-3-[4-ethyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]urea Chemical compound N1C(=O)N(NC(=O)NC=2C(=CC(Br)=CC=2)F)C(=O)C1(CC)CCC1=CC=CC=C1 VRTVMFISQDKPQM-UHFFFAOYSA-N 0.000 claims 1
- LFAJLUPDADECSJ-UHFFFAOYSA-N 1-(4-bromophenyl)-3-(2,4-dioxo-1,3-diazaspiro[4.5]decan-3-yl)urea Chemical compound C1=CC(Br)=CC=C1NC(=O)NN1C(=O)C2(CCCCC2)NC1=O LFAJLUPDADECSJ-UHFFFAOYSA-N 0.000 claims 1
- BANUQILERIYGRP-UHFFFAOYSA-N 1-(4-bromophenyl)-3-(4,4-dicyclopropyl-2,5-dioxoimidazolidin-1-yl)urea Chemical compound C1=CC(Br)=CC=C1NC(=O)NN1C(=O)C(C2CC2)(C2CC2)NC1=O BANUQILERIYGRP-UHFFFAOYSA-N 0.000 claims 1
- AXJMAFCPYUOIEO-UHFFFAOYSA-N 1-(4-bromophenyl)-3-(4,4-diethyl-2,5-dioxoimidazolidin-1-yl)urea Chemical compound O=C1C(CC)(CC)NC(=O)N1NC(=O)NC1=CC=C(Br)C=C1 AXJMAFCPYUOIEO-UHFFFAOYSA-N 0.000 claims 1
- GMHUILWFSUMZOU-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[2,5-dioxo-4,4-di(propan-2-yl)imidazolidin-1-yl]urea Chemical compound O=C1C(C(C)C)(C(C)C)NC(=O)N1NC(=O)NC1=CC=C(Br)C=C1 GMHUILWFSUMZOU-UHFFFAOYSA-N 0.000 claims 1
- CEZPOASFNJODLF-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[4-(hydroxymethyl)-2,5-dioxo-4-propan-2-ylimidazolidin-1-yl]urea Chemical compound O=C1C(C(C)C)(CO)NC(=O)N1NC(=O)NC1=CC=C(Br)C=C1 CEZPOASFNJODLF-UHFFFAOYSA-N 0.000 claims 1
- JAKMGETWSWBBKI-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[4-[2-(2-fluorophenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl]urea Chemical compound N1C(=O)N(NC(=O)NC=2C=CC(Br)=CC=2)C(=O)C1(C)CCC1=CC=CC=C1F JAKMGETWSWBBKI-UHFFFAOYSA-N 0.000 claims 1
- NDJARFOWPZXRND-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[4-[2-(2-hydroxyphenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl]urea Chemical compound N1C(=O)N(NC(=O)NC=2C=CC(Br)=CC=2)C(=O)C1(C)CCC1=CC=CC=C1O NDJARFOWPZXRND-UHFFFAOYSA-N 0.000 claims 1
- LAICXIUZNXHCAS-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[4-[2-(3-fluoro-4-hydroxyphenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl]urea Chemical compound N1C(=O)N(NC(=O)NC=2C=CC(Br)=CC=2)C(=O)C1(C)CCC1=CC=C(O)C(F)=C1 LAICXIUZNXHCAS-UHFFFAOYSA-N 0.000 claims 1
- WHFAIGNZULEGEE-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[4-[2-(3-fluorophenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl]urea Chemical compound N1C(=O)N(NC(=O)NC=2C=CC(Br)=CC=2)C(=O)C1(C)CCC1=CC=CC(F)=C1 WHFAIGNZULEGEE-UHFFFAOYSA-N 0.000 claims 1
- RIJGYMHBXJHWKJ-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[4-[2-(3-hydroxyphenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl]urea Chemical compound N1C(=O)N(NC(=O)NC=2C=CC(Br)=CC=2)C(=O)C1(C)CCC1=CC=CC(O)=C1 RIJGYMHBXJHWKJ-UHFFFAOYSA-N 0.000 claims 1
- ULVPSGVKNAVGBA-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[4-[2-(4-fluorophenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl]urea Chemical compound N1C(=O)N(NC(=O)NC=2C=CC(Br)=CC=2)C(=O)C1(C)CCC1=CC=C(F)C=C1 ULVPSGVKNAVGBA-UHFFFAOYSA-N 0.000 claims 1
- UNUZQNKTEGFHKS-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[4-[2-(4-hydroxyphenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl]urea Chemical compound N1C(=O)N(NC(=O)NC=2C=CC(Br)=CC=2)C(=O)C1(C)CCC1=CC=C(O)C=C1 UNUZQNKTEGFHKS-UHFFFAOYSA-N 0.000 claims 1
- XVAFRERGGZCLSC-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[4-[2-(furan-2-yl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl]urea Chemical compound N1C(=O)N(NC(=O)NC=2C=CC(Br)=CC=2)C(=O)C1(C)CCC1=CC=CO1 XVAFRERGGZCLSC-UHFFFAOYSA-N 0.000 claims 1
- WZUBWDFMPJHXBA-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[4-ethyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]urea Chemical compound N1C(=O)N(NC(=O)NC=2C=CC(Br)=CC=2)C(=O)C1(CC)CCC1=CC=CC=C1 WZUBWDFMPJHXBA-UHFFFAOYSA-N 0.000 claims 1
- CGBOCDQDPMBHIP-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[4-methyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]urea Chemical compound N1C(=O)N(NC(=O)NC=2C=CC(Br)=CC=2)C(=O)C1(C)CCC1=CC=CC=C1 CGBOCDQDPMBHIP-UHFFFAOYSA-N 0.000 claims 1
- OXKOCISLSWJJJB-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[4-methyl-2,5-dioxo-4-(2-thiophen-2-ylethyl)imidazolidin-1-yl]urea Chemical compound N1C(=O)N(NC(=O)NC=2C=CC(Br)=CC=2)C(=O)C1(C)CCC1=CC=CS1 OXKOCISLSWJJJB-UHFFFAOYSA-N 0.000 claims 1
- JWDNVUMPEGUWHM-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[4-methyl-4-[2-(5-methylfuran-2-yl)ethyl]-2,5-dioxoimidazolidin-1-yl]urea Chemical compound O1C(C)=CC=C1CCC1(C)C(=O)N(NC(=O)NC=2C=CC(Br)=CC=2)C(=O)N1 JWDNVUMPEGUWHM-UHFFFAOYSA-N 0.000 claims 1
- ZBXUTNJNUSUWHP-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-(2,4-dioxo-1,3-diazaspiro[4.5]decan-3-yl)urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NN1C(=O)C2(CCCCC2)NC1=O ZBXUTNJNUSUWHP-UHFFFAOYSA-N 0.000 claims 1
- ZGKLRHHWQLBTCW-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-(4-ethyl-4-methyl-2,5-dioxoimidazolidin-1-yl)urea Chemical compound O=C1C(CC)(C)NC(=O)N1NC(=O)NC1=CC=C(Cl)C=C1 ZGKLRHHWQLBTCW-UHFFFAOYSA-N 0.000 claims 1
- DRLYWWBSFZDWQA-UHFFFAOYSA-N 1-(8-methyl-2,4-dioxo-1,3-diazaspiro[4.5]decan-3-yl)-3-(4-methylphenyl)urea Chemical compound C1CC(C)CCC21C(=O)N(NC(=O)NC=1C=CC(C)=CC=1)C(=O)N2 DRLYWWBSFZDWQA-UHFFFAOYSA-N 0.000 claims 1
- CJHLQOOKWGKLJY-UHFFFAOYSA-N 1-[4-methyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]-3-phenylurea Chemical compound N1C(=O)N(NC(=O)NC=2C=CC=CC=2)C(=O)C1(C)CCC1=CC=CC=C1 CJHLQOOKWGKLJY-UHFFFAOYSA-N 0.000 claims 1
- SBUMMNCNWGVRLJ-UHFFFAOYSA-N 2-(4,4-diethyl-2,5-dioxoimidazolidin-1-yl)-n-(4-fluorophenyl)acetamide Chemical compound O=C1C(CC)(CC)NC(=O)N1CC(=O)NC1=CC=C(F)C=C1 SBUMMNCNWGVRLJ-UHFFFAOYSA-N 0.000 claims 1
- GDTCIMYEJLYEBZ-UHFFFAOYSA-N 2-[(3,4-dichlorophenyl)carbamoylamino]-3-phenylpropanoic acid Chemical compound C=1C=C(Cl)C(Cl)=CC=1NC(=O)NC(C(=O)O)CC1=CC=CC=C1 GDTCIMYEJLYEBZ-UHFFFAOYSA-N 0.000 claims 1
- ISENOEPGABALTE-UHFFFAOYSA-N 2-[(3,4-dimethoxyphenyl)carbamoylamino]-3-phenylpropanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1NC(=O)NC(C(O)=O)CC1=CC=CC=C1 ISENOEPGABALTE-UHFFFAOYSA-N 0.000 claims 1
- IPOHNVXMLANJTR-UHFFFAOYSA-N 2-[(4-bromophenyl)carbamoylamino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)NC1=CC=C(Br)C=C1 IPOHNVXMLANJTR-UHFFFAOYSA-N 0.000 claims 1
- KBVPGAVCBMCSJJ-UHFFFAOYSA-N 2-[(4-bromophenyl)carbamoylamino]-n-(2-oxoazepan-3-yl)-3-phenylpropanamide Chemical compound C1=CC(Br)=CC=C1NC(=O)NC(C(=O)NC1C(NCCCC1)=O)CC1=CC=CC=C1 KBVPGAVCBMCSJJ-UHFFFAOYSA-N 0.000 claims 1
- ZNLCEPJDHBSVKN-UHFFFAOYSA-N 2-[(4-chlorophenyl)carbamoylamino]-3-phenylpropanoic acid Chemical compound C=1C=C(Cl)C=CC=1NC(=O)NC(C(=O)O)CC1=CC=CC=C1 ZNLCEPJDHBSVKN-UHFFFAOYSA-N 0.000 claims 1
- ROLQGUCDHGPXCI-UHFFFAOYSA-N 2-[(4-methoxyphenyl)carbamoylamino]-3-phenylpropanoic acid Chemical compound C1=CC(OC)=CC=C1NC(=O)NC(C(O)=O)CC1=CC=CC=C1 ROLQGUCDHGPXCI-UHFFFAOYSA-N 0.000 claims 1
- HHILIFOAVORNLC-UHFFFAOYSA-N 2-[1-[(4-bromo-2-fluorophenyl)carbamoylamino]-2,5-dioxo-4-propan-2-ylimidazolidin-4-yl]-n-(2-hydroxyethyl)acetamide Chemical compound O=C1C(C(C)C)(CC(=O)NCCO)NC(=O)N1NC(=O)NC1=CC=C(Br)C=C1F HHILIFOAVORNLC-UHFFFAOYSA-N 0.000 claims 1
- CLOKOIGWQXYIQV-UHFFFAOYSA-N 2-[1-[(4-bromophenyl)carbamoylamino]-2,5-dioxo-4-propan-2-ylimidazolidin-4-yl]-n-(2-diethoxyphosphorylethyl)acetamide Chemical compound O=C1C(CC(=O)NCCP(=O)(OCC)OCC)(C(C)C)NC(=O)N1NC(=O)NC1=CC=C(Br)C=C1 CLOKOIGWQXYIQV-UHFFFAOYSA-N 0.000 claims 1
- WDEOQUSGGWZNGR-UHFFFAOYSA-N 2-[1-[(4-bromophenyl)carbamoylamino]-2,5-dioxo-4-propan-2-ylimidazolidin-4-yl]-n-(2-hydroxyethyl)acetamide Chemical compound O=C1C(C(C)C)(CC(=O)NCCO)NC(=O)N1NC(=O)NC1=CC=C(Br)C=C1 WDEOQUSGGWZNGR-UHFFFAOYSA-N 0.000 claims 1
- MUMNJJSIAKMOIQ-UHFFFAOYSA-N 2-[2-[1-[(4-bromo-2-fluorophenyl)carbamoylamino]-4-ethyl-2,5-dioxoimidazolidin-4-yl]ethyl]benzoic acid Chemical compound N1C(=O)N(NC(=O)NC=2C(=CC(Br)=CC=2)F)C(=O)C1(CC)CCC1=CC=CC=C1C(O)=O MUMNJJSIAKMOIQ-UHFFFAOYSA-N 0.000 claims 1
- LONIAWYGZGQBSJ-UHFFFAOYSA-N 2-[2-[1-[(4-bromophenyl)carbamoylamino]-2,5-dioxo-4-propan-2-ylimidazolidin-4-yl]ethyl]benzoic acid Chemical compound N1C(=O)N(NC(=O)NC=2C=CC(Br)=CC=2)C(=O)C1(C(C)C)CCC1=CC=CC=C1C(O)=O LONIAWYGZGQBSJ-UHFFFAOYSA-N 0.000 claims 1
- SEDWRZCVHBRJMW-UHFFFAOYSA-N 2-[2-[1-[(4-bromophenyl)carbamoylamino]-4-ethyl-2,5-dioxoimidazolidin-4-yl]ethyl]benzoic acid Chemical compound N1C(=O)N(NC(=O)NC=2C=CC(Br)=CC=2)C(=O)C1(CC)CCC1=CC=CC=C1C(O)=O SEDWRZCVHBRJMW-UHFFFAOYSA-N 0.000 claims 1
- GWOULRCUFTYSHG-LBPRGKRZSA-N 2-[[(2s)-2-[(4-bromo-2-fluorophenyl)carbamoylamino]-4-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1F GWOULRCUFTYSHG-LBPRGKRZSA-N 0.000 claims 1
- QYDQTIDVJOKRJM-NSHDSACASA-N 2-[[(2s)-2-[(4-bromo-2-fluorophenyl)carbamoylamino]pentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CCC)NC(=O)NC1=CC=C(Br)C=C1F QYDQTIDVJOKRJM-NSHDSACASA-N 0.000 claims 1
- VKACGCIFXOGMSV-HNNXBMFYSA-N 2-[[(2s)-2-[(4-bromophenyl)carbamoylamino]-3-phenylpropanoyl]amino]acetic acid Chemical compound C([C@@H](C(=O)NCC(=O)O)NC(=O)NC=1C=CC(Br)=CC=1)C1=CC=CC=C1 VKACGCIFXOGMSV-HNNXBMFYSA-N 0.000 claims 1
- WUZBUPYJADEKRK-ZDUSSCGKSA-N 2-[[(2s)-2-[(4-bromophenyl)carbamoylamino]-4-methylpentanoyl]amino]-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 WUZBUPYJADEKRK-ZDUSSCGKSA-N 0.000 claims 1
- LASJSIMHDHTROE-LBPRGKRZSA-N 2-[[(2s)-2-[(4-bromophenyl)carbamoylamino]-4-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 LASJSIMHDHTROE-LBPRGKRZSA-N 0.000 claims 1
- APOCNKWKDAQCPO-NSHDSACASA-N 2-[[(2s)-2-[(4-bromophenyl)carbamoylamino]-4-methylsulfanylbutanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CCSC)NC(=O)NC1=CC=C(Br)C=C1 APOCNKWKDAQCPO-NSHDSACASA-N 0.000 claims 1
- ARRWDYXSLZNBRO-NSHDSACASA-N 2-[[(2s)-2-[(4-bromophenyl)carbamoylamino]pentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CCC)NC(=O)NC1=CC=C(Br)C=C1 ARRWDYXSLZNBRO-NSHDSACASA-N 0.000 claims 1
- NOUPHQZUCIKPRJ-ZDUSSCGKSA-N 2-[[(2s)-4-methyl-2-[(4-methylsulfanylphenyl)carbamoylamino]pentanoyl]amino]acetic acid Chemical compound CSC1=CC=C(NC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O)C=C1 NOUPHQZUCIKPRJ-ZDUSSCGKSA-N 0.000 claims 1
- WGOPETHLVCCHMW-LBPRGKRZSA-N 2-[[(2s)-4-methyl-2-[[4-(trifluoromethyl)phenyl]carbamoylamino]pentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(C(F)(F)F)C=C1 WGOPETHLVCCHMW-LBPRGKRZSA-N 0.000 claims 1
- QTXGBSUJMGBGRI-SDBXPKJASA-N 2-[[(2s,3s)-2-[(4-bromo-2-fluorophenyl)carbamoylamino]-3-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)NC1=CC=C(Br)C=C1F QTXGBSUJMGBGRI-SDBXPKJASA-N 0.000 claims 1
- WKPPVFWLQCDKQE-ZANVPECISA-N 2-[[(2s,3s)-2-[(4-bromophenyl)carbamoylamino]-3-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)NC1=CC=C(Br)C=C1 WKPPVFWLQCDKQE-ZANVPECISA-N 0.000 claims 1
- ABRLDZBSIGBGNO-UHFFFAOYSA-N 2-[[2-[(4-bromophenyl)carbamoylamino]-2,4-dimethylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)C(C)(CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 ABRLDZBSIGBGNO-UHFFFAOYSA-N 0.000 claims 1
- DABXKTZCTUPXLJ-UHFFFAOYSA-N 2-[[2-[(4-bromophenyl)carbamoylamino]-2-ethylbutanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)C(CC)(CC)NC(=O)NC1=CC=C(Br)C=C1 DABXKTZCTUPXLJ-UHFFFAOYSA-N 0.000 claims 1
- MXJJTHDBFXAKDT-UHFFFAOYSA-N 2-[[2-[(4-bromophenyl)carbamoylamino]-3-(1h-indol-3-yl)propanoyl]amino]acetic acid Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NCC(=O)O)NC(=O)NC1=CC=C(Br)C=C1 MXJJTHDBFXAKDT-UHFFFAOYSA-N 0.000 claims 1
- DCLHXYQPZHIEBY-ZDUSSCGKSA-N 2-methyl-2-[[(2s)-4-methyl-2-[[4-(trifluoromethyl)phenyl]carbamoylamino]pentanoyl]amino]propanoic acid Chemical compound OC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(C(F)(F)F)C=C1 DCLHXYQPZHIEBY-ZDUSSCGKSA-N 0.000 claims 1
- SZWNUFZCGVXWAA-INIZCTEOSA-N 3-[[(2s)-2-[(4-bromophenyl)carbamoylamino]-3-phenylpropanoyl]amino]propanoic acid Chemical compound C([C@@H](C(=O)NCCC(=O)O)NC(=O)NC=1C=CC(Br)=CC=1)C1=CC=CC=C1 SZWNUFZCGVXWAA-INIZCTEOSA-N 0.000 claims 1
- ZGVMLLVJMVVXBC-UHFFFAOYSA-N 3-[[2-[1-[(4-bromo-2-fluorophenyl)carbamoylamino]-2,5-dioxo-4-propan-2-ylimidazolidin-4-yl]acetyl]amino]propanoic acid Chemical compound O=C1C(C(C)C)(CC(=O)NCCC(O)=O)NC(=O)N1NC(=O)NC1=CC=C(Br)C=C1F ZGVMLLVJMVVXBC-UHFFFAOYSA-N 0.000 claims 1
- WPFDTZMZCVLQNC-UHFFFAOYSA-N 3-[[2-[1-[(4-bromophenyl)carbamoylamino]-2,5-dioxo-4-propan-2-ylimidazolidin-4-yl]acetyl]amino]propanoic acid Chemical compound O=C1C(C(C)C)(CC(=O)NCCC(O)=O)NC(=O)N1NC(=O)NC1=CC=C(Br)C=C1 WPFDTZMZCVLQNC-UHFFFAOYSA-N 0.000 claims 1
- WOEXOKHOZTZPNP-UHFFFAOYSA-N 3-phenyl-2-(pyridin-3-ylcarbamoylamino)propanoic acid Chemical compound C=1C=CN=CC=1NC(=O)NC(C(=O)O)CC1=CC=CC=C1 WOEXOKHOZTZPNP-UHFFFAOYSA-N 0.000 claims 1
- GAADLCAGWAYSGH-UHFFFAOYSA-N 3-phenyl-2-[[4-(trifluoromethoxy)phenyl]carbamoylamino]propanoic acid Chemical compound C=1C=C(OC(F)(F)F)C=CC=1NC(=O)NC(C(=O)O)CC1=CC=CC=C1 GAADLCAGWAYSGH-UHFFFAOYSA-N 0.000 claims 1
- SLIMOPZXCUSPOX-UHFFFAOYSA-N 3-phenyl-2-[[4-(trifluoromethyl)phenyl]carbamoylamino]propanoic acid Chemical compound C=1C=C(C(F)(F)F)C=CC=1NC(=O)NC(C(=O)O)CC1=CC=CC=C1 SLIMOPZXCUSPOX-UHFFFAOYSA-N 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- LENLZYPMKWPZDQ-UHFFFAOYSA-O [4-[(1-carboxy-2-phenylethyl)carbamoylamino]phenyl]-oxoazanium Chemical compound C1=CC=CC(=C1)CC(C(=O)O)NC(=O)NC1=CC=C([NH+]=O)C=C1 LENLZYPMKWPZDQ-UHFFFAOYSA-O 0.000 claims 1
- 235000011054 acetic acid Nutrition 0.000 claims 1
- 229960000583 acetic acid Drugs 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- ALQCCNUYRKDOMQ-UHFFFAOYSA-N ethyl 3-[(4-bromophenyl)carbamoylamino]-2,4-dioxo-1,3-diazaspiro[4.5]decane-8-carboxylate Chemical compound C1CC(C(=O)OCC)CCC21C(=O)N(NC(=O)NC=1C=CC(Br)=CC=1)C(=O)N2 ALQCCNUYRKDOMQ-UHFFFAOYSA-N 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000035168 lymphangiogenesis Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- YXELRUXLSGTZEG-UHFFFAOYSA-N methyl 2-[2-[1-[(4-bromophenyl)carbamoylamino]-4-ethyl-2,5-dioxoimidazolidin-4-yl]ethyl]benzoate Chemical compound N1C(=O)N(NC(=O)NC=2C=CC(Br)=CC=2)C(=O)C1(CC)CCC1=CC=CC=C1C(=O)OC YXELRUXLSGTZEG-UHFFFAOYSA-N 0.000 claims 1
- SKHUYSZEXQZFCZ-LBPRGKRZSA-N methyl 2-[[(2s)-2-[(4-bromophenyl)carbamoylamino]pentanoyl]amino]acetate Chemical compound COC(=O)CNC(=O)[C@H](CCC)NC(=O)NC1=CC=C(Br)C=C1 SKHUYSZEXQZFCZ-LBPRGKRZSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- BSDVLPAKRFBAAT-UHFFFAOYSA-N n-(4-bromophenyl)-2-(1,3-dioxo-3a,4,7,7a-tetrahydroisoindol-2-yl)acetamide Chemical compound C1=CC(Br)=CC=C1NC(=O)CN1C(=O)C2CC=CCC2C1=O BSDVLPAKRFBAAT-UHFFFAOYSA-N 0.000 claims 1
- UUIRITXPYAOMCC-UHFFFAOYSA-N n-(4-bromophenyl)-2-(2,4-dioxo-1,3-diazaspiro[4.5]decan-3-yl)acetamide Chemical compound C1=CC(Br)=CC=C1NC(=O)CN1C(=O)C2(CCCCC2)NC1=O UUIRITXPYAOMCC-UHFFFAOYSA-N 0.000 claims 1
- CJPRDIDULAXJBO-UHFFFAOYSA-N n-(4-bromophenyl)-2-(2,5-dioxo-4,4-dipropylimidazolidin-1-yl)acetamide Chemical compound O=C1C(CCC)(CCC)NC(=O)N1CC(=O)NC1=CC=C(Br)C=C1 CJPRDIDULAXJBO-UHFFFAOYSA-N 0.000 claims 1
- SIZAXIVFKSSJKA-UHFFFAOYSA-N n-(4-bromophenyl)-2-(4,4-diethyl-2,5-dioxoimidazolidin-1-yl)acetamide Chemical compound O=C1C(CC)(CC)NC(=O)N1CC(=O)NC1=CC=C(Br)C=C1 SIZAXIVFKSSJKA-UHFFFAOYSA-N 0.000 claims 1
- DEQTXYOBBWGLMS-UHFFFAOYSA-N n-(4-bromophenyl)-2-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)acetamide Chemical compound O=C1C(C)(C)NC(=O)N1CC(=O)NC1=CC=C(Br)C=C1 DEQTXYOBBWGLMS-UHFFFAOYSA-N 0.000 claims 1
- VFHJIKCFNPPHJA-UHFFFAOYSA-N n-(4-bromophenyl)-2-(4-cyclopropyl-4-methyl-2,5-dioxoimidazolidin-1-yl)acetamide Chemical compound O=C1C(C)(C2CC2)NC(=O)N1CC(=O)NC1=CC=C(Br)C=C1 VFHJIKCFNPPHJA-UHFFFAOYSA-N 0.000 claims 1
- KHDSTUZMHJIGKK-UHFFFAOYSA-N n-(4-bromophenyl)-2-(4-ethyl-2,5-dioxo-4-phenylimidazolidin-1-yl)acetamide Chemical compound O=C1C(CC)(C=2C=CC=CC=2)NC(=O)N1CC(=O)NC1=CC=C(Br)C=C1 KHDSTUZMHJIGKK-UHFFFAOYSA-N 0.000 claims 1
- LTSWISVZDXQGQX-UHFFFAOYSA-N n-(4-bromophenyl)-2-(4-ethyl-4-methyl-2,5-dioxoimidazolidin-1-yl)acetamide Chemical compound O=C1C(CC)(C)NC(=O)N1CC(=O)NC1=CC=C(Br)C=C1 LTSWISVZDXQGQX-UHFFFAOYSA-N 0.000 claims 1
- OUBSCADNRKXOMJ-UHFFFAOYSA-N n-(4-bromophenyl)-2-[4-methyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]acetamide Chemical compound N1C(=O)N(CC(=O)NC=2C=CC(Br)=CC=2)C(=O)C1(C)CCC1=CC=CC=C1 OUBSCADNRKXOMJ-UHFFFAOYSA-N 0.000 claims 1
- QJCHCMGTTSZGEE-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(4,4-diethyl-2,5-dioxoimidazolidin-1-yl)acetamide Chemical compound O=C1C(CC)(CC)NC(=O)N1CC(=O)NC1=CC=C(Cl)C=C1 QJCHCMGTTSZGEE-UHFFFAOYSA-N 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- DVNAAJJNFZBNOH-AWEZNQCLSA-N propan-2-yl 2-[[(2s)-2-[(4-bromophenyl)carbamoylamino]pentanoyl]amino]acetate Chemical compound CC(C)OC(=O)CNC(=O)[C@H](CCC)NC(=O)NC1=CC=C(Br)C=C1 DVNAAJJNFZBNOH-AWEZNQCLSA-N 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- QVSRSKPJAWLALL-UHFFFAOYSA-N stk257733 Chemical compound C1=CC(Br)=CC=C1NC(=O)CN1C(=O)C2C(C=C3)CC3C2C1=O QVSRSKPJAWLALL-UHFFFAOYSA-N 0.000 claims 1
- PQECWSRQAOCYDI-ROUUACIJSA-N tert-butyl (2s)-2-[[(2s)-2-[(4-bromophenyl)carbamoylamino]-4-methylpentanoyl]amino]pentanoate Chemical compound CC(C)(C)OC(=O)[C@H](CCC)NC(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 PQECWSRQAOCYDI-ROUUACIJSA-N 0.000 claims 1
- PDQSMERWJDWTOG-INIZCTEOSA-N tert-butyl 2-[[(2s)-2-[(4-bromophenyl)carbamoylamino]-4-methylpentanoyl]-methylamino]acetate Chemical compound CC(C)(C)OC(=O)CN(C)C(=O)[C@H](CC(C)C)NC(=O)NC1=CC=C(Br)C=C1 PDQSMERWJDWTOG-INIZCTEOSA-N 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- -1 —CH 2 -heterocycle Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361773773P | 2013-03-06 | 2013-03-06 | |
| US61/773,773 | 2013-03-06 | ||
| PCT/US2014/020245 WO2014138037A1 (en) | 2013-03-06 | 2014-03-04 | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017157335A Division JP6496786B2 (ja) | 2013-03-06 | 2017-08-17 | 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用 |
| JP2017157334A Division JP6602351B2 (ja) | 2013-03-06 | 2017-08-17 | 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512193A JP2016512193A (ja) | 2016-04-25 |
| JP2016512193A5 true JP2016512193A5 (enExample) | 2017-04-13 |
| JP6196327B2 JP6196327B2 (ja) | 2017-09-13 |
Family
ID=50382628
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561536A Active JP6196327B2 (ja) | 2013-03-06 | 2014-03-04 | 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用 |
| JP2017157335A Active JP6496786B2 (ja) | 2013-03-06 | 2017-08-17 | 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用 |
| JP2017157334A Active JP6602351B2 (ja) | 2013-03-06 | 2017-08-17 | 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用 |
| JP2019043934A Active JP6672500B2 (ja) | 2013-03-06 | 2019-03-11 | 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017157335A Active JP6496786B2 (ja) | 2013-03-06 | 2017-08-17 | 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用 |
| JP2017157334A Active JP6602351B2 (ja) | 2013-03-06 | 2017-08-17 | 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用 |
| JP2019043934A Active JP6672500B2 (ja) | 2013-03-06 | 2019-03-11 | 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9850264B2 (enExample) |
| EP (2) | EP2964213B1 (enExample) |
| JP (4) | JP6196327B2 (enExample) |
| KR (2) | KR102227201B1 (enExample) |
| CN (2) | CN105007909B (enExample) |
| AR (1) | AR095034A1 (enExample) |
| AU (3) | AU2014225992B2 (enExample) |
| BR (2) | BR112015021371B1 (enExample) |
| CA (2) | CA3133264A1 (enExample) |
| CL (3) | CL2015002485A1 (enExample) |
| ES (2) | ES2835825T3 (enExample) |
| IL (3) | IL241012B (enExample) |
| MX (2) | MX364916B (enExample) |
| MY (1) | MY207109A (enExample) |
| PH (3) | PH12020500285B1 (enExample) |
| RU (2) | RU2663911C2 (enExample) |
| SG (2) | SG11201507113RA (enExample) |
| TW (1) | TWI616200B (enExample) |
| WO (1) | WO2014138037A1 (enExample) |
| ZA (1) | ZA201505134B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2770989T (pt) * | 2011-10-26 | 2018-12-04 | Allergan Inc | Derivados de amida de aminoácidos substituídos por n-ureia como moduladores de recetor tipo-1 do recetor de péptidos formil (fprl-1) |
| WO2013158597A1 (en) * | 2012-04-16 | 2013-10-24 | Allergan, Inc. | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| WO2013171687A1 (en) | 2012-05-16 | 2013-11-21 | Actelion Pharmaceuticals Ltd | 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
| MA37618B1 (fr) | 2012-05-16 | 2017-08-31 | Actelion Pharmaceuticals Ltd | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| CA2899804A1 (en) | 2013-03-06 | 2014-09-12 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases |
| RU2663911C2 (ru) * | 2013-03-06 | 2018-08-13 | Аллерган, Инк. | Применение агонистов формилпептидного рецептора 2 для лечения воспалительных заболеваний глаз |
| AR096686A1 (es) | 2013-06-25 | 2016-01-27 | Actelion Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx |
| AU2014290618B2 (en) * | 2013-07-16 | 2018-04-05 | Allergan, Inc. | Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators |
| ES2639798T3 (es) | 2013-07-18 | 2017-10-30 | Idorsia Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano con puente sustituidos con piperazina como agonistas del receptor ALX |
| AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
| US9663457B2 (en) | 2014-04-09 | 2017-05-30 | Allergan, Inc. | Carbamoyl hydrazine derivatives as formyl peptide modulators |
| US10301269B2 (en) | 2014-05-21 | 2019-05-28 | Allergan, Inc. | Imidazole derivatives as formyl peptide receptor modulators |
| EP3271327A4 (en) * | 2015-03-19 | 2018-11-21 | University of Maryland, Baltimore | Runx2 transcription factor inhibitors and uses thereof |
| US10858314B2 (en) | 2015-05-27 | 2020-12-08 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
| WO2017172761A1 (en) * | 2016-03-28 | 2017-10-05 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
| CA3020316A1 (en) * | 2016-04-12 | 2017-10-19 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
| CA3130536A1 (en) | 2016-10-06 | 2018-04-12 | Daiichi Sankyo Company, Limited | Urea derivative |
| CN109134533B (zh) | 2017-06-27 | 2020-08-11 | 维眸生物科技（上海）有限公司 | 一种含磷化合物及其制备和应用 |
| CN107814773B (zh) * | 2017-11-13 | 2020-05-22 | 西安交通大学 | 含有喹唑啉酮的二芳基脲类化合物及其制备方法和应用 |
| RU2712229C2 (ru) * | 2018-05-17 | 2020-01-27 | Закрытое акционерное общество "Институт экспериментальной фармакологии" | Эфиры тригидроксигептаеновой кислоты в качестве агонистов fpr2 рецептора |
| KR102429281B1 (ko) * | 2020-05-25 | 2022-08-05 | (주)노바셀테크놀로지 | 신규 안구건조증 치료용 약학적 조성물 |
| IT202100004964A1 (it) * | 2021-03-03 | 2022-09-03 | Univ Degli Studi Di Bari Aldo Moro | Agonisti del recettore fpr2 (formyl peptide receptor 2) e loro uso nel trattamento del disturbo dello spettro autistico. |
| JP2022151437A (ja) * | 2021-03-26 | 2022-10-07 | 均 石井 | 網膜炎治療薬。 |
| WO2025233915A1 (en) * | 2024-05-10 | 2025-11-13 | Allgenesis Biotherapeutics Inc. | Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases |
| WO2025239980A1 (en) * | 2024-05-13 | 2025-11-20 | University Of Virginia Patent Foundation | Compounds for the inhibition of kifc3, methods of making the same, and pharmaceutical compositions comprising the same |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4521210A (en) | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| JPS63232846A (ja) | 1987-03-20 | 1988-09-28 | Haruo Ogura | 新規な固定相担体 |
| AU667995B2 (en) * | 1993-02-15 | 1996-04-18 | Bayer Aktiengesellschaft | New pseudopeptides having an antiviral action |
| US6423689B1 (en) * | 1997-12-22 | 2002-07-23 | Warner-Lambert Company | Peptidyl calcium channel blockers |
| AU6909300A (en) * | 1999-08-20 | 2001-03-19 | Merck & Co., Inc. | Substituted ureas as cell adhesion inhibitors |
| EP1162194A1 (en) | 2000-06-06 | 2001-12-12 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
| DE10063008A1 (de) | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
| EP1537075B1 (en) | 2002-09-05 | 2009-07-01 | Neurosearch A/S | Diarylurea derivatives and their use as chloride channel blockers |
| WO2004041850A1 (ja) * | 2002-11-07 | 2004-05-21 | Takeda Pharmaceutical Company Limited | 新規なｆｐｒｌ１リガンドおよびその用途 |
| US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| EP1692502A2 (en) | 2003-11-07 | 2006-08-23 | Acadia Pharmaceuticals Inc. | Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation |
| EP1695961A4 (en) | 2003-12-17 | 2007-10-24 | Takeda Pharmaceutical | UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE |
| WO2006065755A2 (en) | 2004-12-13 | 2006-06-22 | Glaxo Group Limited | Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists |
| WO2007076055A2 (en) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| US20080008694A1 (en) * | 2006-07-05 | 2008-01-10 | Elgebaly Salwa A | Methods to prevent and treat diseases |
| EP2492278A1 (en) * | 2006-09-18 | 2012-08-29 | Compugen Ltd. | Antibodies against an agonist of G-protein coupled receptors and its use indiagnosis and therapy |
| WO2009097997A1 (de) | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
| US20100035932A1 (en) * | 2008-08-07 | 2010-02-11 | Schepetkin Igor A | Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof |
| WO2010104306A2 (ko) * | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| CA2803920A1 (en) | 2010-06-24 | 2011-12-29 | Richard Beard | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| CA2819457A1 (en) | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| WO2012109544A1 (en) | 2011-02-11 | 2012-08-16 | Allergan, Inc. | Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators |
| US8653299B2 (en) | 2011-03-17 | 2014-02-18 | Allergan, Inc. | Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US20120329873A1 (en) | 2011-06-17 | 2012-12-27 | Li yong-xin | D-serine for the treatment of visual system disorders |
| CA2841983A1 (en) | 2011-07-11 | 2013-01-17 | Allergan, Inc. | Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators |
| PT2770989T (pt) * | 2011-10-26 | 2018-12-04 | Allergan Inc | Derivados de amida de aminoácidos substituídos por n-ureia como moduladores de recetor tipo-1 do recetor de péptidos formil (fprl-1) |
| US8492556B2 (en) * | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US8541577B2 (en) * | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| CA2864893A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators |
| WO2013158597A1 (en) | 2012-04-16 | 2013-10-24 | Allergan, Inc. | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| RU2663911C2 (ru) * | 2013-03-06 | 2018-08-13 | Аллерган, Инк. | Применение агонистов формилпептидного рецептора 2 для лечения воспалительных заболеваний глаз |
-
2014
- 2014-03-04 RU RU2015136774A patent/RU2663911C2/ru active
- 2014-03-04 SG SG11201507113RA patent/SG11201507113RA/en unknown
- 2014-03-04 EP EP14712888.8A patent/EP2964213B1/en active Active
- 2014-03-04 AU AU2014225992A patent/AU2014225992B2/en active Active
- 2014-03-04 SG SG10201801471RA patent/SG10201801471RA/en unknown
- 2014-03-04 KR KR1020157024036A patent/KR102227201B1/ko active Active
- 2014-03-04 CN CN201480012204.5A patent/CN105007909B/zh active Active
- 2014-03-04 JP JP2015561536A patent/JP6196327B2/ja active Active
- 2014-03-04 MX MX2015011593A patent/MX364916B/es active IP Right Grant
- 2014-03-04 EP EP20205401.1A patent/EP3795148B1/en active Active
- 2014-03-04 ES ES14712888T patent/ES2835825T3/es active Active
- 2014-03-04 BR BR112015021371-5A patent/BR112015021371B1/pt active IP Right Grant
- 2014-03-04 PH PH1/2020/500285A patent/PH12020500285B1/en unknown
- 2014-03-04 KR KR1020207023766A patent/KR102290134B1/ko active Active
- 2014-03-04 CA CA3133264A patent/CA3133264A1/en active Pending
- 2014-03-04 BR BR122017004254-8A patent/BR122017004254B1/pt active IP Right Grant
- 2014-03-04 WO PCT/US2014/020245 patent/WO2014138037A1/en not_active Ceased
- 2014-03-04 MY MYPI2019001743A patent/MY207109A/en unknown
- 2014-03-04 MX MX2019005541A patent/MX393070B/es unknown
- 2014-03-04 US US14/196,047 patent/US9850264B2/en active Active
- 2014-03-04 RU RU2018127997A patent/RU2768730C2/ru active
- 2014-03-04 CN CN201910497947.0A patent/CN110279684B/zh active Active
- 2014-03-04 CA CA2898301A patent/CA2898301C/en active Active
- 2014-03-04 ES ES20205401T patent/ES3036990T3/es active Active
- 2014-03-06 TW TW103107761A patent/TWI616200B/zh active
- 2014-03-06 AR ARP140100732A patent/AR095034A1/es not_active Application Discontinuation
-
2015
- 2015-07-16 ZA ZA2015/05134A patent/ZA201505134B/en unknown
- 2015-08-24 PH PH12015501858A patent/PH12015501858B1/en unknown
- 2015-09-01 IL IL241012A patent/IL241012B/en active IP Right Grant
- 2015-09-04 CL CL2015002485A patent/CL2015002485A1/es unknown
-
2017
- 2017-07-21 US US15/656,766 patent/US10208071B2/en active Active
- 2017-08-17 JP JP2017157335A patent/JP6496786B2/ja active Active
- 2017-08-17 JP JP2017157334A patent/JP6602351B2/ja active Active
- 2017-10-06 CL CL2017002526A patent/CL2017002526A1/es unknown
- 2017-10-06 CL CL2017002527A patent/CL2017002527A1/es unknown
-
2018
- 2018-05-28 AU AU2018203719A patent/AU2018203719B2/en active Active
- 2018-11-27 IL IL263314A patent/IL263314B/en active IP Right Grant
-
2019
- 2019-01-22 US US16/254,438 patent/US10899780B2/en active Active
- 2019-03-11 JP JP2019043934A patent/JP6672500B2/ja active Active
- 2019-09-06 AU AU2019226215A patent/AU2019226215B2/en active Active
-
2020
- 2020-02-07 PH PH12020500286A patent/PH12020500286A1/en unknown
- 2020-03-11 IL IL273208A patent/IL273208A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018127997A (ru) | Применение агонистов формилпептидного рецептора 2 для лечения воспалительных заболеваний глаз | |
| JP2016512194A5 (enExample) | ||
| RU2015134778A (ru) | Применение агонистов формилпептидного рецептора 2 для лечения дерматологических заболеваний | |
| RU2485114C2 (ru) | Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов | |
| RU2004127925A (ru) | N3-алкилированные бензимидазольные производные в качестве ингибиторов мек | |
| JP2013517283A5 (enExample) | ||
| JP2013516415A5 (enExample) | ||
| JP2017523972A5 (enExample) | ||
| JP2012525431A5 (enExample) | ||
| JP2016504378A5 (enExample) | ||
| JP2013532713A5 (enExample) | ||
| RU2018112237A (ru) | Новые бициклические соединения в качестве дуальных ингибиторов atx/ca | |
| JP2016528189A5 (enExample) | ||
| RU2014142598A (ru) | Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в | |
| HRP20220314T1 (hr) | Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao plazma kallikrein inhibitori | |
| JP2004518726A5 (enExample) | ||
| JP2010531345A5 (enExample) | ||
| JP2014511869A5 (enExample) | ||
| JP2004508304A5 (enExample) | ||
| RU2006102510A (ru) | Бензимидазольные, бензтиазольные и бензоксазольные производные и их применение в качестве модуляторов lta4h | |
| JP2010523674A5 (enExample) | ||
| RU2014122753A (ru) | Производные 2,5-диоксоимидазолидин-1-ил-3-фенилмочевины в качестве модуляторов формилпептидного рецептора 1 (fprl-1) | |
| RU2014122750A (ru) | Производные арилмочевины в качестве модуляторов n-формилпептидного-1 рецептора (fprl-1) | |
| RU2008137612A (ru) | Амидное производное или его соли | |
| JP2013506637A5 (enExample) |